Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH1 | Q92800 | 12/20 | 0.92 |
| ▸ | EZH2 | Q15910 | 11/20 | 0.91 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.90 |
| ▸ | EED | O75530 | 1/20 | 0.90 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.90 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.90 |
| ▸ | RBBP7 | Q16576 | 1/20 | 0.90 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.90 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351394 | 1.00 | EZH1 (0.92) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL12180659 | 0.94 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL2591377 | 0.94 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL30459645 | 0.94 | EZH1 (1.00) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL2594776 | 0.93 | EZH1 (0.87) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL21271616 | 0.92 | EZH2 (1.00) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL31505792 | 0.92 | EZH2 (1.00) | EZH1EZH2EEDRBBP4SUZ12 | |
| SCHEMBL21284988 | 0.91 | EZH1 (0.88) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL25272476 | 0.91 | EZH1 (0.84) | EZH1EZH2PRMT3EEDRBBP4 | |
| SCHEMBL30459505 | 0.91 | EZH1 (0.84) | EZH1EZH2PRMT3EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | FONDATION ASILE DES AVEUGLES (CH) | 2026-05-26 | — | — | US | claimed |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-01-20 | — | — | US | claimed |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | WISTAR INST (US) | 2025-01-09 | — | — | US | claimed |
| US-20240335452-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | CULLGEN (SHANGHAI), INC. (CN) | 2024-10-10 | — | — | US | claimed |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | The Wistar Institut of Anatomy and Biology (US) | 2024-07-16 | — | — | US | claimed |
| EP-3823671-B1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FOND ASILE DES AVEUGLES (CH) | 2024-02-07 | — | — | EP | claimed |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-08-19 | — | — | US | claimed |
| US-20210213013-A1 | INHIBITION OF PRC2 SUBUNITS TO TREAT EYE DISORDERS | FONDATION ASILE DES AVEUGLES (CH) | 2021-07-15 | — | — | US | claimed |
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2021-01-28 | — | — | US | claimed |
| WO-2019195443-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-10-10 | — | — | WO | claimed |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | WISTAR INST (US) | 2019-06-27 | — | — | US | claimed |
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-05-09 | — | — | US | claimed |
| WO-2017192290-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC DRUGS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-11-09 | — | — | WO | claimed |
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250276079-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-04 | — | — | US | disclosed |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| WO-2016079321-A1 | ANTAGONISTS OF SETDB2 FOR USE IN THE THERAPY OF INFECTIOUS DISEASES | CEMM FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2016-05-26 | — | — | WO | disclosed |
| WO-2015123326-A1 | CHROMATIN-ACTIVITY-BASED CHEMOPROTEOMIC (CHAC) METHODS AND SYSTEMS FOR DISEASE MARKER DISCOVERY AND DEVELOPMENT | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150160246-A1 | DEVICES AND METHODS FOR DETERMINING AND/OR ISOLATING CELLS SUCH AS CIRCULATING CANCER OR FETAL CELLS | ANALIZA, INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023077-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | EZH1 31/4885EZH2 2/4885PRMT3 5/4885 |
| US-20250276079-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITOR | EZH1, EZH2, EED | EZH1 1/4885EZH2 2/4885PRMT3 220/4885 |
| US-12636283-B2 | Inhibition of PRC2 subunits to treat eye disorders | EZH2, EZH1, EED | EZH1 2/4885EZH2 1/4885PRMT3 834/4885 |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | EZH2, HDAC6, HDAC1 | EZH1 14/4885EZH2 1/4885PRMT3 187/4885 |
| US-20190134025-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH1 17/4885EZH2 2/4885PRMT3 4/4885 |
| US-12629364-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs | EZH2, CARM1, PRMT6 | EZH1 10/4885EZH2 1/4885PRMT3 5/4885 |
| US-20210251987-A1 | Methods of Treating Cancers Overexpressing Carm1 With EZH2 Inhibitors and Platinum-Based Antineoplastic Drugs | CARM1, EZH2, PRMT1 | EZH1 16/4885EZH2 2/4885PRMT3 4/4885 |
| US-20250009736-A1 | METHODS OF TREATING CANCERS OVEREXPRESSING CARM1 WITH EZH2 INHIBITORS AND A PARP INHIBITOR | CARM1, EZH2, PRMT1 | EZH1 31/4885EZH2 2/4885PRMT3 5/4885 |
| US-20240335452-A1 | COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA | EZH2, BCL6, BMI1 | EZH1 14/4885EZH2 1/4885PRMT3 280/4885 |
| US-20250082629-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | EZH1 602/4885EZH2 8/4885PRMT3 548/4885 |
| US-12529091-B2 | ATAC-array for prediction of disease-free survival in pancreatic cancer | ABCC1, EPCAM, ABCF2 | EZH1 147/4885EZH2 582/4885PRMT3 2465/4885 |
| US-12036222-B2 | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor | CARM1, EZH2, PRMT1 | EZH1 31/4885EZH2 2/4885PRMT3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.